FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 307:1301-1304 November 18, 1982 Number 21 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We detected a severe defect in concanavalin A-induced suppressor-cell activity in 22 patients with "autoimmune" chronic active hepatitis and in 26 patients with hepatitis B surface antigen (HBsAg)-positive chronic active hepatitis, as compared with 20 control subjects (P less than 0.01). Normal values were observed in 21 patients with "autoimmune" hepatitis in whom a remission had been induced and maintained by treatment with prednisolone. When lymphocytes from patients with autoimmune chronic active hepatitis were preincubated with low-dose prednisolone in vitro, suppressor-cell activity was substantially improved (P less than 0.01), but no clear effect of prednisolone was seen in cells from patients with HBsAg-positive chronic active hepatitis. The loss of suppressor-cell activity in chronic active hepatitis may allow liver damage to continue, and the reversal of the defect in the autoimmune form of the disease by administration of low-dose prednisolone provides a plausible explanation for the efficacy of this treatment. The contrasting in vitro responses to prednisolone in autoimmune and HBsAg-positive chronic active hepatitis suggest that the fundamental nature of the suppressor-cell defect may be different in these two forms of the disease.

This article has been cited by other articles:

• Krawitt, E. L. (2006). Autoimmune Hepatitis. NEJM 354: 54-66 [Full Text]  
• Krawitt, E. L. (1996). Autoimmune Hepatitis. NEJM 334: 897-903 [Full Text]  
• Johnson, P. J., McFarlane, I. G., Williams, R. (1995). Azathioprine for Long-Term Maintenance of Remission in Autoimmune Hepatitis. NEJM 333: 958-963 [Abstract] [Full Text]